Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Relypsa Inc. (cardiovascular and metabolic therapeutics) netted $79.7mm through the initial public offering of 7.8mm common shares (including a partial exercise of the overallotment) at $11. The company had originally planned to sell 6.9mm shares between $16-19. Some of Relypsa's current shareholders and one of its executive officers agreed to purchase a total of 1.8mm shares (about $19.9mm) through the financing.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?